Longitudinal profile of circulating T follicular helper lymphocytes parallels anti-HLA sensitization in renal transplant recipients.


Journal

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638

Informations de publication

Date de publication:
01 2019
Historique:
received: 25 04 2018
revised: 27 05 2018
accepted: 19 06 2018
pubmed: 28 6 2018
medline: 17 4 2020
entrez: 28 6 2018
Statut: ppublish

Résumé

Antibody-mediated rejection is responsible for 30%-50% of renal graft failures. Differentiation of B cells into antibody-producing plasmablasts depends on the collaboration of follicular helper T cells (Tfh). We analyzed circulating Tfh (cTfh) in kidney recipients and studied cTfh relationship with anti-HLA antibody production and graft outcome. cTfh were longitudinally analyzed in a prospective cohort of patients (n = 206), pre- and posttransplantation. Clinical data, HLA sensitization, and cTfh function were recorded. Both pretransplant and 6-month posttransplant cTfh were able to derive IgG-producing plasmablasts. Pretransplant cTfh was decreased in patients, especially in those who received dialysis. However, these cells were increased in patients with previous allograft or transfusions and in HLA-sensitized recipients. After transplantation cTfh expanded, significantly more in patients who developed de novo anti-HLA antibodies than in patients who remained unsensitized. Augmented pretransplant cTfh positively correlated with higher intensity of pretransplant anti-HLA class I and with de novo anti-HLA class I and anti-HLA class II antibodies. Consistently, pretransplantation cTfh were higher in patients who experienced acute rejection (HR = 1.14 [1.04-1.25]). Thus, we show a role for Tfh in anti-HLA sensitization and rejection. Multicenter studies with additional patient cohorts are needed to validate these results. Immunosuppressive drugs targeting Tfh could be useful to improve outcomes.

Identifiants

pubmed: 29947147
doi: 10.1111/ajt.14987
pii: S1600-6135(22)08901-8
doi:

Substances chimiques

Antibodies 0
Biomarkers 0
HLA Antigens 0
Isoantibodies 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

89-97

Subventions

Organisme : Sociedad Madrileña de Trasplantes
ID : PI17/082
Pays : International
Organisme : FIS-Instituto de Salud Carlos III
ID : PIE13/00045
Pays : International
Organisme : ERDF (European Regional Development Fund)
ID : PIE13/00045
Pays : International
Organisme : Fundación José Luis Castaño
Pays : International

Informations de copyright

© 2018 The American Society of Transplantation and the American Society of Transplant Surgeons.

Auteurs

Francisco Luis Cano-Romero (FL)

Department of Immunology, Hospital 12 de Octubre, Madrid, Spain.
Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.

Rocío Laguna Goya (R)

Department of Immunology, Hospital 12 de Octubre, Madrid, Spain.
Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
Department of Immunology, Universidad Complutense de Madrid, Madrid, Spain.
Department of Pharmaceutical Sciences, Universidad San Pablo CEU, Madrid, Spain.

Alberto Utrero-Rico (A)

Department of Immunology, Hospital 12 de Octubre, Madrid, Spain.
Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.

Elena Gómez-Massa (E)

Department of Immunology, Hospital 12 de Octubre, Madrid, Spain.
Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.

Daniel Arroyo-Sánchez (D)

Department of Immunology, Hospital 12 de Octubre, Madrid, Spain.
Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.

Patricia Suárez-Fernández (P)

Department of Immunology, Hospital 12 de Octubre, Madrid, Spain.
Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.

David Lora (D)

Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

Amado Andrés (A)

Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
Department of Nephrology, Hospital 12 de Octubre, Madrid, Spain.

Mª José Castro-Panete (MJ)

Department of Immunology, Hospital 12 de Octubre, Madrid, Spain.
Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.

Estela Paz-Artal (E)

Department of Immunology, Hospital 12 de Octubre, Madrid, Spain.
Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
Department of Immunology, Universidad Complutense de Madrid, Madrid, Spain.
Department of Pharmaceutical Sciences, Universidad San Pablo CEU, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH